Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #44 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Jagsonpal Pharmaceuticals is targeting 12%-14% organic growth for the coming years. Jagsonpal Pharmaceuticals targets 12%-14% organic revenue growth going forward, maintaining previous guidance of 15% growth (including inorganic).
From Jagsonpal Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jagsonpal Pharmaceuticals is targeting 12%-14% organic growth for the coming years.
- The company maintains an overall growth guidance of around 15% for the current year, including the annualized contribution from the acquired Yash Pharma business.
- Growth drivers include increased MR (medical representative) productivity and focused marketing efforts.
- Around 9%-10% of growth is organic, with the rest from full-quarter contribution of acquisitions.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus is primarily on inorganic growth via acquisitions rather than capex on manufacturing or infrastructure.
- The company is open to acquisitions of brands or businesses within India, particularly in subchronic therapeutic segments.
- They have cash on hand (~Rs. 161 crores) and generate strong monthly cash flows (~Rs. 5 crores/month) to support potential acquisitions.
- No pressure to use cash for acquisitions; if no strategic deal meets criteria, funds may be returned to shareholders.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jagsonpal Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q1 FY26 results?
Jagsonpal Pharmaceuticals is targeting 12%-14% organic growth for the coming years. Jagsonpal Pharmaceuticals targets 12%-14% organic revenue growth going forward, maintaining previous guidance of 15% growth (including inorganic).
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
- Focus is primarily on inorganic growth via acquisitions rather than capex on manufacturing or infrastructure. - The company is open to acquisitions of brands or businesses within India, particularly in subchronic therapeutic segments. - They have cash on hand (~Rs.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.